Alexion Pharmaceuticals (NASDAQ:ALXN) dropped slightly amid mild profit booking and the last known price was $123.95 per share. The price decreased by -0.01 points or -0.01% which made the investors to buy on weakness. For the latest trading session, the net money flow was recorded at $3.79 million. The total upticks were valued at $49.97 million and the total downticks aggregated to $46.18 million, thereby putting the up/down ratio at 1.08,. The shares have seen a change in the share price of -1% on a weekly basis.In a big block trade which occurred today, the total uptick value was $4.63 million and the total downtick value was $0, resulting in an up/down ratio of 0. The net money flow for the block trade was calculated to be $4.63 million.
The stock has recorded a 20-day Moving Average of 12.21% and the 50-Day Moving Average is 14.37%. The company shares have dropped 35.07% in the past 52 Weeks. On July 23, 2015 The shares registered one year high of $208.88 and one year low was seen on June 20, 2016 at $123.79. The 50-day moving average is $141.52 and the 200 day moving average is recorded at $151.78. S&P 500 has rallied 1.93% during the last 52-weeks.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $124.57 and $122.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $124.83. The buying momentum continued till the end and the stock did not give up its gains. It closed at $124.14, notching a gain of 0.15% for the day. The total traded volume was 2,691,077 . The stock had closed at $123.96 on the previous day.
Currently the company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.06% . Institutional Investors own 98.92% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -2.25%. On the companys insider trading activities, Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, unloaded 918 shares at an average price of $135.72 on June 13, 2016. The total amount of the transaction was worth $124,591, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.